Add as a preferred source on GoogleAktis Oncology’s Q3 Net Loss Nearly Doubles to $29.9 Million
Research and development expenses rose to $32.1 million as the company began a third Phase 1b trial and expects its cash to fund operations into 2029.
Aktis Oncology’s third-quarter net loss nearly doubled to $29.9 million as research and development spending climbed; the company expects its cash resources to fund its operating plan into 2029.
The loss compared with $15.5 million in the year-earlier quarter. Research and development expenses increased to $32.1 million from $16.5 million, while collaboration revenue rose to $3.9 million from $1.6 million.
As of Sept. 30, 2026, Aktis held $492.9 million in cash, cash equivalents and marketable securities. The company expects those funds to support its operating plan into 2029.
Aktis also began BActinium-2, its third Phase 1b trial. The study is evaluating AKY-2519 in non-small cell lung cancer and other B7-H3-expressing solid tumors. The company opened initial backfill cohorts in its ongoing NECTINIUM-2 and BActinium-1 trials.
Aktis expects to present preliminary data for AKY-1189 in the first quarter of 2027 and for AKY-2519 in 2027.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.